Literature DB >> 23604522

Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes.

Pasquale Niscola, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Luca Cupelli, Gianfranco Catalano, Alessio Perrotti, Paolo de Fabritiis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23604522     DOI： 10.1007/s00520-013-1818-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  22 in total

1.  Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.

Authors:  G Verhoef; H Van den Berghe; M Boogaerts
Journal:  Leukemia       Date:  1992-08       Impact factor: 11.528

2.  Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.

Authors:  M A Aloe Spiriti; R Latagliata; P Niscola; A Cortelezzi; M Francesconi; D Ferrari; E Volpe; M Clavio; A Grossi; M Tambone Reyes; P Musto; M E Mitra; A Azzarà; D Pagnini; G D'Arena; A Spadano; E Balleari; P Pecorari; E Capochiani; E De Biasi; D Perego; B Monarca; F Pisani; G Scaramella; M C Petti
Journal:  Ann Hematol       Date:  2004-11-30       Impact factor: 3.673

3.  Durable erythroid response after discontinuation of epoetin-alpha: an unexpected outcome in a patient with myelodysplastic syndrome.

Authors:  Pasquale Niscola; Marco Giovannini; Andrea Tendas; Laura Scaramucci; Alessio Perrotti; Paolo De Fabritiis
Journal:  Blood Transfus       Date:  2013-02-21       Impact factor: 3.443

4.  rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples.

Authors:  Gian Matteo Rigolin; Matteo Della Porta; Renato Bigoni; Francesco Cavazzini; Maria Ciccone; Antonella Bardi; Antonio Cuneo; Gianluigi Castoldi
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

Review 5.  Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.

Authors:  Luca Malcovati
Journal:  Clin Lymphoma Myeloma       Date:  2009

6.  A hematological remission by clonal hematopoiesis after treatment with recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin in a patient with therapy-related myelodysplastic syndrome.

Authors:  M Bessho; Y Itoh; S Kataumi; N Kawai; A Matsuda; I Jinnai; M Saitoh; K Hirashima; M Minamihisamatsu
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156

7.  Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey.

Authors:  Pasquale Niscola; Claudio Cartoni; Claudio Romani; Gregorio Antonio Brunetti; Gianna Maria D'Elia; Luca Cupelli; Andrea Tendas; Paolo de Fabritiis; Franco Mandelli; Robin Foà
Journal:  Ann Hematol       Date:  2007-04-21       Impact factor: 3.673

Review 8.  Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review.

Authors:  Deborah J Pinchon; Simon J Stanworth; Carolyn Dorée; Susan Brunskill; Derek R Norfolk
Journal:  Am J Hematol       Date:  2009-10       Impact factor: 10.047

9.  In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.

Authors:  Gian Matteo Rigolin; Matteo Della Porta; Maria Ciccone; Anna Maria Bugli; Letizia Zenone Bragotti; Endri Mauro; Chiara Fraulini; Antonella Russo Rossi; Antonella Bardi; Antonio Cuneo; Gianluigi Castoldi
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

10.  Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.

Authors:  Jaroslav Cermak; Petra Kacirkova; Dana Mikulenkova; Kyra Michalova
Journal:  Leuk Res       Date:  2009-07-30       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.